# Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999

> **NCT02393027** · EARLY_PHASE1 · TERMINATED · sponsor: **University Hospital, Tours** · enrollment: 16 (actual)

## Conditions studied

- Idiopathic Parkinson Disease

## Interventions

- **DRUG:** [18F] LBT-999 PET

## Key facts

- **NCT ID:** NCT02393027
- **Lead sponsor:** University Hospital, Tours
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03
- **Primary completion:** 2016-11
- **Final completion:** 2017-05
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Enough inclusions for interpretation
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02393027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02393027, "Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02393027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*